Additional mutations, such as in cyclin-dependent kinase inhibitor 2A (CDKN2A) or the promoter of the human telomerase reverse transcriptase (hTERT) and chromosomal copy number aberrations have been frequently reported in low-CSD melanoma [16]. This evidence concerns the gene CDKN2A and melanoma.